BEST ADD-ON THERAPY GIVING EFFECTIVE RESPONSES (BADGER)

给出有效反应的最佳附加疗法 (BADGER)

• 批准号: 7603411
• 负责人: Robert Strunk
• 金额: $ 0.18万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603411
• 关键词: Adrenal Cortex Hormones; Asthma; Badger; Breathing; Child; Childhood Asthma; Clinical; Computer Retrieval of Information on Scientific Projects Database; Dose; Forced expiratory volume function; Funding; Genetic Crossing Over; Grant; Institution; Outcome; Pharmaceutical Preparations; Pulmonary function tests; Recording of previous events; Research; Research Design; Research Personnel; Resources; Source; United States National Institutes of Health; base; day; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Monotherapy with inhaled corticosteroid (ICS) in mild to moderate persistent asthma in children has been shown to be beneficial in most children. The natural next step in studying asthma therapy options is determining the optimal add-on medication (increasing ICS, LABA or LTRA) to ICS when monotherapy with ICS at that dose is inadequate to control asthma satisfactorily. BADGER, or Best Add-on Therapy Giving Effective Responses, will answer the question about best add-on medication in 180 children (36 per clinical center) who have a history of mild to moderate asthma and are not completely controlled on low dose ICS. The study design is a triple cross over with each child receiving each add-on medication. The primary outcomes will be treatment response based on asthma exacerbation, asthma control days, and change in forced expiratory volume in one second (lung function testing).

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 在儿童的轻度至中度持续性哮喘中吸入的皮质类固醇（ICS）单一疗法已被证明对大多数儿童都是有益的。 研究哮喘治疗方案的自然下一步是确定当与该剂量的ICS单一疗法不足以满足地控制哮喘时，最佳的附加药物（增加ICS，LABA或LTRA）对IC进行了。 badge或最佳的附加疗法有效反应，将回答有关有180名儿童（每个临床中心36个）最佳辅助药物的问题，他们患有轻度至中度哮喘的病史，并且不能完全控制低剂量的ICS。 研究设计是一个三重交叉，每个孩子都接受每种附加药物。 主要结果将是基于哮喘恶化，哮喘控制日的治疗反应，以及一秒钟内强制呼气量的变化（肺功能测试）。